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SUMMARY
Conjugated estrogens (CE) delay the onset of type 2
diabetes (T2D) in postmenopausal women, but the
mechanism is unclear. In T2D, the endoplasmic retic-
ulum (ER) fails to promote proinsulin folding and, in
failing to do so, promotes ER stress and b cell
dysfunction. We show that CE prevent insulin-defi-
cient diabetes in male and in female Akita mice using
a model of misfolded proinsulin. CE stabilize the
ER-associated protein degradation (ERAD) system
and promote misfolded proinsulin proteasomal
degradation. This involves activation of nuclear and
membrane estrogen receptor-a (ERa), promoting
transcriptional repression and proteasomal degra-
dation of the ubiquitin-conjugating enzyme and
ERAD degrader, UBC6e. The selective ERa modu-
lator bazedoxifene mimics CE protection of b cells
in females but not in males.
INTRODUCTION
Type 2 diabetes (T2D) is increasingly considered a protein mis-
folding disorder (Wang and Kaufman, 2016). Early in the disease,
as insulin-producing pancreatic b cells increase proinsulin syn-
thesis to adapt to nutrient overload and insulin resistance, the
proinsulin load overwhelms the capacity of the endoplasmic re-
ticulum (ER) for proper proinsulin folding and trafficking (Back
and Kaufman, 2012; Eizirik and Cnop, 2010; Papa, 2012).
Chronic exposure of b cells to glucose, lipids, and cytokines
further compromises the ability of the ER to promote folding of
proinsulin. The resultant ER stress triggers an unfolded protein
response (UPR) to enhance proinsulin folding/trafficking, remove
misfolded proinsulin, and restore protein homeostasis. If protein
misfolding is not resolved, b cells ultimately die. The causality
between proinsulin misfolding and b cell failure is best exempli-
fied by insulin gene mutation syndromes in which mutant and
misfolded proinsulin triggers irreparable UPR, leading to early
insulin-deficient diabetes in humans and in the Akita mouse
(Liu et al., 2010).
The female hormone 17b-estradiol (E2) protects rodent b cells
in vivo against multiple proapoptotic insults (Kilic et al., 2014; Le
May et al., 2006; Liu et al., 2009, 2013; Liu and Mauvais-Jarvis,
2009; Tiano et al., 2011; Tiano and Mauvais-Jarvis, 2012;
Wong et al., 2010), and this protection is conserved in human is-
lets (Kilic et al., 2014; Liu et al., 2009, 2013; Liu andMauvais-Jar-
vis, 2009; Tiano et al., 2011; Tiano and Mauvais-Jarvis, 2012;
Wong et al., 2010). That E2 action in b cells prevents apoptosis
induced by excess lipids and glucose, oxidative stress, and
proinflammatory cytokines—all conditions producing ER stress
and activating the UPR (Wang and Kaufman, 2016)—led us to
envision a unifyingmechanism inwhich activation of estrogen re-
ceptors (ERs) in b cells mitigates ER stress and helps resolve the
UPR. Notably, large randomized-controlled trials have shown
that menopausal hormone therapy (MHT) with conjugated estro-
gens (CE) reduces the incidence of T2D in women (Espeland
et al., 1998; Kanaya et al., 2003; Manson et al., 2013; Manson
and Kaunitz, 2016; Margolis et al., 2004; Salpeter et al., 2006).
The exact mechanism of this anti-diabetic effect is poorly under-
stood and is not explained by a decrease in adiposity or insulin
resistance (Mauvais-Jarvis et al., 2017b; Santen et al., 2010).
In fact, CE therapy seems to protect b cell function in postmen-
opausal women (Mauvais-Jarvis et al., 2017b). Age-associated
failure of protein folding (which is accelerated by menopause)
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(Zhou et al., 2016) allows misfolded proteins to accumulate,
leading to the b cell dysfunction and vulnerability associated
with aging (Taylor, 2016). Therefore, in postmenopausal women,
CE treatment maymitigate age-associated ER stress in b cells to
protect insulin secretion and delay diabetes. To explore this hy-
pothesis, we used mice and cells heterozygous for the Akita
spontaneous mutation (Ins2+/Akita) as a model of extreme insulin
misfolding. We tested the effect of CE alone or in combination
with the selective estrogen receptor modulator (SERM) baze-
doxifene (BZA), a novel menopausal treatment that provides
the benefits of CE, while simultaneously protecting uterine and
breast tissues from estrogenic stimulation (Kharode et al.,
2008; Komm, 2008, 2011; Lindsay et al., 2009).
RESULTS
CE and BZA Differentially Protect Islets and Prevent
Diabetes in Male and in Female Akita Mice
We studied male Akita mice at 5 weeks of age, when they were
already hyperglycemic. Treatment with CE decreased random-
fed blood glucose to normoglycemic levels compared to vehicle,
but BZA did not (Figure 1A). Further, BZA seemed to impair the
ability of CE in preventing hyperglycemia, as the combination
CE+BZA was not as efficient as CE alone in preventing hypergly-
cemia (Figure 1A). The blood insulin/glucose (I/G) ratio, an index
of b cell function, was higher in CE- and CE+BZA-treated male
mice compared to the vehicle- and BZA-treated groups (Fig-
ure 1B), indicating that CE and, to a lesser extent, CE+BZA,
but not BZA alone, helped preserve insulin secretion in these
mice. Fasting hyperglycemia was significantly decreased in
CE-treated mice only (Figure S1A). Following an intraperitoneal
glucose tolerance test (IP-GTT), CE-treated male Akita mice dis-
played better glucose tolerance compared to their littermates
treated with vehicle, BZA, or the combination CE+BZA (Fig-
ure 1C). Accordingly, CE-treated male Akita mice exhibited
higher plasma I/G index of b cell function at 30 min into the
GTT compared to other groups (Figure 1D). The endogenous
hormone E2 exhibited the same anti-diabetic effect asCE in adult
male Akita mice (Figures S1B and S1C). To determine whether
the combination of CE with BZA protects insulin secretion and
prevents diabetes when administered prior to the development
of hyperglycemia, we studied normoglycemic, prepubertal
3-week-old male Akita mice. In these young mice, treatment
with CE+BZA prevented the onset of hyperglycemia (Figure 1E)
and was associated with a higher I/G index of b cell function
compared to vehicle (Figure 1F).
Female Akita mice are not as hyperglycemic as males and are
therefore rarely used in studies. Indeed, female Akita mice ex-
hibited mild hyperglycemia at 3 weeks of age compared to
male littermates (cf. Figures 1G and 1E). Given the observed pro-
tective effect of CE and E2 in Akita males, we ovariectomized
(OVX) the Akita females to test for the protective effect of endog-
enous E2. When ovariectomized before puberty, vehicle-treated
OVX female Akita mice developed more severe hyperglycemia
compared to control sham-operated Akita littermates, suggest-
ing that they were protected by ovarian E2 (Figure 1G). Treatment
with CE, BZA, or CE+BZA reduced the severity of hyperglycemia
in OVX Akita mice compared with vehicle-treated OVX Akita
mice (Figure 1G). Importantly, unlike in males, in OVX Akita
mice, BZA alone prevented hyperglycemia to an extent similar
to CE (Figure 1G). Accordingly, the I/G index of b cell function
was improved by treatment of OVX Akita mice with CE, BZA,
andCE+BZA compared to those treated with vehicle (Figure 1H).
To validate that the combination of CE with BZA could also pre-
vent diabetes in female Akita mice after sexual maturation, we
treated female Akita mice with OVX after puberty, followed by
treatment with CE+BZA. At 75 days of age, intact female Akita
mice were mildly hyperglycemic compared to littermate males
of the same age (cf. Figures 1A and 1I), suggesting that female
Akita mice are protected from diabetes by endogenous E2.
Vehicle-treated OVX mature Akita mice developed hyperglyce-
mia at levels similar to those observed in males (Figure 1i). In
contrast, treatment with CE+BZA totally prevented OVX mature
Akita mice from developing hyperglycemia (Figure 1i). Therefore,
in young and in mature female Akita mice, CE and BZA similarly
prevent the development of insulin-deficient diabetes. These re-
sults demonstrate that CE prevent b cell failure and the develop-
ment of insulin-deficient diabetes in male and OVX female Akita
mice. However, BZA alone prevents b cell failure and the devel-
opment of diabetes in females, but not in males.
Consistent with the effect of estrogens on blood glucose
described above, treatment of OVX female Akita mice with CE,
BZA, and CE+BZA preserved b cell mass compared to vehicle
(Figure 2A). In OVX mice, treatments with CE, BZA, or CE+BZA
decreased b cell apoptosis (Figure 2B) without affecting b cell
proliferation (data not shown). Furthermore, b cells of vehicle-
treated mature OVX female Akita mice exhibited dilated ER
and enlarged mitochondria compared to wild-type (WT) and
ovary-intact Akita female mice, suggesting that endogenous E2
prevents ER stress and mitochondrial damage in Akita b cells
(Figures 2C–2E). Consistent with the protection of b cell function
described earlier (Figure 1H), treatment of OVX Akita mice with
CE+BZA helped retain the normal morphology of b cell ER and
mitochondria (Figures 2C–2E). In adult male Akita mice, treat-
ment with CE, and to a lesser extent CE+BZA, also helped retain
higher b cell mass (Figure 2F) and pancreas insulin content (Fig-
ure 2G) compared to vehicle-treated mice, while BZA alone had
no effect on these parameters (Figures 2F and 2G). The endog-
enous hormone E2 exhibited the same protective effect as CE
on b cell apoptosis and pancreas insulin content in male Akita
mice (Figures S2A and S2B). Accordingly, CE or CE+BZA, but
not BZA alone, decreased b cell apoptosis (Figure 2H) with no
effect on b cell proliferation (Figure S2C). In prepubertal
3-week-old male Akita mice, consistent with the protection of
b cell function and hyperglycemia described earlier (Figure 1F),
treatment with the combination CE+BZA prevented the ER
stress and swelling of mitochondria (Figures 2I–2K).
Together, these results demonstrate that CE and BZA prevent
ER stress, mitochondrial structural alterations, and b cell
apoptosis and help retain b cell mass and insulin secretion in
OVX female Akita mice.
CE and BZA Differentially Prevent ER Stress in Male
Ins2+/Akita Cells and in Female Akita Islet Cells
Because islets from male Akita mice, but not females, are de-
stroyed early, we studied b cell protection from ER stress in
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cultured male Ins2+/Akita insulinoma cells derived from male
Akita b cells (Tsutsumi et al., 2004) and dispersed islet cells
from female Akita mice. We exacerbated protein misfolding
and ER stress pharmacologically in vitro using low-dose thap-
sigargin (Tg), an inhibitor of the sarco/endoplasmic reticulum
Ca2+ ATPase (SERCA). Treatment with Tg decreases ER
Ca2+, inhibiting Ca2+-dependent chaperone activity in the ER
and promoting misfolded protein accumulation (Rogers et al.,
1995). We quantified the expression of the proapoptotic
component of the UPR, C/EBP homologous protein (CHOP)
(Oyadomari and Mori, 2004). Exposure to Tg increased CHOP
immunoreactivity and expression in male and in female Akita
cells (Figures 3A–3C). Consistent with results obtained Akita
mice, in Tg-exposed female Akita b cells, treatment with CE,
Figure 1. Effect of CE and BZA on Diabetes in Akita Mice
(A) Random-fed blood glucose (and corresponding AUC) in male Akita mice treated with vehicle, CE, BZA, or CE+BZA at the indicated age (n = 10–11 distinct
animals/condition).
(B) Insulin/glucose ratio with corresponding AUC measured in mice from (A).
(C) IP-GTT with corresponding AUC in 8-week-old male Akita mice from (A).
(D) Insulin/glucose ratio at 30 min from the GTT in mice from (C).
(E) Random-fed blood glucose and corresponding AUC measured in young male WT and Akita mice treated with V or CE+BZA (n = 4–5 distinct animals/
condition).
(F) Plasma insulin/blood glucose ratio in mice from (E).
(G) Random-fed blood glucose (and corresponding AUC) in OVX or sham-operated female Akita mice treated with compounds (n = 5–9 distinct animals/
condition).
(H) Insulin/glucose ratio and corresponding AUC in mice from (G).
(I) Random-fed blood glucose and corresponding AUC in mature OVX or sham-operated female Akita mice treated with vehicle or CE/BZA (n = 4–5 distinct
animals/condition).
Data are shown as mean ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001.
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BZA, and CE+BZA significantly decreased nuclear CHOP
immunoreactivity (Figure 3A). In contrast, in Tg-exposed
male Ins2+/Akita cells, CE and CE+BZA, but not BZA alone,
decreased Tg-induced expression of CHOP (Figures 3B
and 3C).
The UPR comprises three arms, mediated by three trans-
membrane ER proximal sensors of unfolded proteins, activating
transcription factor 6 (ATF6), inositol-requiring transmembrane
kinase/endonuclease 1a (IRE1a), and pancreatic ER kinase
(PERK) (Figure 3D). We studied the effect of estrogens on
each UPR arm in Tg-exposed Ins2+/Akita cells using the
following UPR markers: immunoglobulin heavy chain-binding
protein (BiP) for ATF6 activation, spliced X-box binding pro-
tein-1 (sXBP-1) mRNA for IRE1a activation, and activating
Figure 2. Effect of CE and BZA on b Cell Mass in Akita Mice
(A) Representative immunofluorescent (IF) staining of islets from OVX and sham-operated female Akita mice stained for insulin (red), glucagon (green), and nuclei
(blue) and b cell mass quantification in mice from Figure 1G at 45 days.
(B) b cell apoptosis quantification by TUNEL staining in islet sections from (A) (n = 3 distinct animals/condition).
(C) Representative TEM images of mitochondria and ER from b cells of 3-week-old female WT and Akita mice treated with CE+BZA for 6 days.
(D and E) Quantification of the area of mitochondria (D) and dilation of ER (E) in mice from (C) (n = 4).
(F) Representative immunohistochemistry (IHC) staining of islets frommale Akita mice stained for insulin (red), glucagon (green), and nuclei (blue) and b cell mass
quantification in mice from Figure 1A at 68 days (n = 5–7 distinct animals/condition).
(G) Pancreatic insulin content in male Akita mice from (F) (n = 3–4).
(H) b cell apoptosis quantification in mice of (F) (n = 3–4).
(I) Representative TEM images of mitochondria and ER from b cells of 3-week-old male WT and Akita mice treated with vehicle or CE+BZA for 3 days.
(J and K) Quantification of the area of mitochondria (J) and ER dilation (K) in mice from (I) (n = 4 distinct animals/condition).
Data are shown as mean ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001.
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transcription factor 4 (ATF4) mRNA and elf2a phosphorylation
for PERK activation (Figure 3D). Treatment with CE or CE+BZA,
but not BZA alone, decreased Tg-induced protein expression
of BiP (Figure 3E), the mRNA expression of sXBP-1 (Figure 3F)
and ATF4 (Figure 3G). CE also decreased Tg-induced phos-
phorylation of elf2a (Figure S3A). Together, these results
confirm results obtained with CHOP that CE help resolve
UPR in these cells.
CE and BZA Protect Female Akita b Cells against ER
Stress via ERa
Three estrogen receptors are expressed in b cells: ERa, ERb, and
the G-protein-coupled estrogen receptor (GPER). To determine
which receptor(s) is (are) involved in the protective role of CE
and BZA against ER stress in female mice, we studied dispersed
islets of female ERa knockout (ERaKO), ERb knockout (ERbKO).
and GPER knockout (GPERKO) mice and their corresponding
Figure 3. Effects of CE and BZA on ER Stress in Ins2+/Akita b Cells and Human Islets
(A) Dispersed islets from female Akita mice were treated with the indicated compounds for 24 hr, followed by exposure to Tg for 4 hr. Representative images of IF
staining for CHOP (red), insulin (green), and nuclei (blue) and quantification of b cells with CHOP+ nuclei relative to vehicle (n = 5 distinct experiments).
(B) Western blot of CHOP expression with quantification by densitometry in male Ins2+/Akita cells treated like in (a) (n = 6 distinct experiments).
(C) Male Ins2+/Akita b cells were treated like in (a). Representative images of IF staining for CHOP (red), insulin (green), and nuclei (blue) and quantification of b cells
with CHOP+ nuclei relative to vehicle (n = 6 distinct experiments).
(D) Schematic representation of three arms of the UPR.
(E) Male Ins2+/Akita cells were treated like in (A). Representative western blot for BiP and relative BiP protein expression levels quantified by densitometry
(n = 4 experiments).
(F and G) qRT-PCR quantification of spliced XBP-1 mRNA (F) and ATF4 mRNA in male Ins2+/Akita cells (G) treated like in (A) (n = 8–9 distinct experiments).
(H) Dispersed islets from femaleWT and ERaKOmice were treated like in (A). Representative images of IF staining for CHOP (red), insulin (green), and nuclei (blue)
and quantification of b cells with CHOP+ nuclei relative to vehicle (n = 3 distinct experiments).
(I) Human islets from female donors were cultured like in (A). Representative western blot for CHOP protein expression levels and quantification (n = 3 distinct
donors).
Data are shown as mean ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001.
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WT littermates. The protective effect of CE and BZA against Tg-
inducedCHOP nuclear expression inWT b cells was abolished in
ERaKO b cells (Figure 3H), but not in ERbKO and GPERKO b
cells (Figures S3B and S3C), indicating that ERa was indispens-
able for CE and BZA prevention of ER stress in female b cells.
Importantly, CE, BZA, and CE+BZA also suppressed Tg-induc-
tion of CHOP expression in cultured islets obtained from adult
human female organ donors (Figure 3I).
CE Activation of ERa Promotes Misfolded Proinsulin
Degradation by Stabilizing the ER-Associated Protein
Degradation System
We reasoned that if activation of ERa protects b cells from ER
stress in the presence of mutant Akita proinsulin, it may promote
misfolded proinsulin degradation. The ER-associated protein
degradation (ERAD) pathway plays a critical role in cellular pro-
teostasis by removing unfolded proteins via retrograde transport
from the ER back to the cytosol, where these unfolded proteins
are degraded by the ubiquitin-proteasome system (Qi et al.,
2017; Smith et al., 2011). The major instrument of the ERAD in
mammals is the hydroxymethylglutaryl reductase degradation
protein 1 (HRD1), an E3 ubiquitin ligase located in the ER mem-
brane (Figure 4A) (Kaneko et al., 2010; Qi et al., 2017; Smith et al.,
2011). We used male Ins2+/Akita cells to study the effect of CE on
ERAD, as the absence of an equivalent cell line in females
precludes detailed molecular studies of the mechanisms. In
Ins2+/Akita cells exposed to Tg, treatment with CE and CE+BZA,
but not BZA alone, increased HRD1 protein expression, and this
was reproduced by the selective ERa agonist PPT (Figures 4B
and 4C), suggesting that HRD1 is the effector activated by
CE-ERa to promote the ubiquitination of misfolded insulin.
HRD1 can promote the ubiquitination of misfolded Akita C96Y
proinsulin in COS-7 cells (Allen et al., 2004). To ascertain whether
HRD1 is instrumental in CE’s ability to promote the ubiquitination
Figure 4. CE-ERa Promotes Misfolded
Proinsulin Degradation via HRD1-ERAD
Stabilization
(A) Diagram of misfolded protein degradation
via ERAD including misfolded protein retro-
translocation to the cytosol via E3 ubiquitin ligase
HRD1 and its scaffold adaptor SEL1L followed by
HRD1-mediated ubiquitination and proteasomal
degradation.
(B andC)Male Ins2+/Akita cells were treatedwith CE
and BZA (B) or PPT (C) for 24 hr, followed by
exposure to Tg for 4 hr. Representative image of
western blot for HRD1 expression and quantifica-
tion (n = 4–7 distinct experiments/condition).
(D) COS-7 cells were transfected with HA-WT
proinsulin or HA-C96Y proinsulin along with ERa
and FLAG-ubiquitin in the absence or presence of
HRD-1. Cells were treated with CE for 24 hr, fol-
lowed by exposure to Tg for 4 hr. Co-immuno-
precipitations were carried out using anti-HA
antibody followed by western blotting using anti-
FLAG or anti-HA antibodies (left). Quantification of
relative proinsulin ubiquitination (middle) and pro-
insulin stability (right) (n = 3 distinct experiments/
condition).
(E) Male Ins2+/Akita cells were treated like in (B),
followed by qRT-PCR quantification of HRD1
mRNA (n = 8 experiments).
(F–I) Male Ins2+/Akita cells were treated with cyclo-
heximide (CHX) plus Tg and either vehicle (F and G)
or CE (H and I) in the presence (G and I) or in the
absence (F and H) of MG132 for the indicated time
course. Western blots for HRD1 were performed
on cell lysates. Relative HRD1 protein levels were
determined by densitometry and were normalized
to that obtained at time 0 (n = 4–6 distinct experi-
ments/condition).
(J) Islets from female human donors were treated
like in (B). Representative image of western blot for
HRD1 expression and bar graph of quantification
(n = 3).
Data are shown as mean ± SEM. *p < 0.05;
**p < 0.01; and ***p < 0.001.
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and degradation of C96Y proinsulin, we co-transfected COS-7
cells with ERa, HRD1, and ubiquitin and either WT or C96Y pro-
insulin. In this cellular system, in the absence of HRD1 there
were slightly higher levels of ubiquitin modification of WT
compared to C96Y proinsulin (Figure 4D), and CE promoted a
modest reduction in WT proinsulin levels (Figure 4D). Most
importantly, in the presence of HRD1, CE increased ubiquitin
modification ofWT and C96Y-proinsulin with a relatively larger in-
crease in HRD1-mediated ubiquitin modification of C96Y-proin-
sulin (Figure 4D). As a result, in the presence of HRD1, CE
increased C96Y-proinsulin destabilization without affecting WT
proinsulin stability (Figures 4D and S4). Thus, in the presence
of HRD1, CE preferentially promote the degradation of misfolded
C96Y-proinsulin.
Interestingly, in Ins2+/Akita cells exposed to ER stress, CE
increased HRD1 protein without increasing HRD1 mRNA levels
(cf. Figures 4B–4E), suggesting that CE promote HRD1 protein
stabilization via post-translational mechanisms. To determine
to what extent CE treatment stabilizes HRD1 protein, we studied
HRD1 protein turnover in the presence of the protein synthesis
inhibitor cycloheximide (CHX) to block de novo protein synthe-
sis. In the absence of CE, HRD1 was rapidly degraded (Fig-
ure 4F), and this was blocked by the proteasome inhibitor
MG132, demonstrating that HRD1 turnover is dependent on
proteasomal degradation (Figure 4G). However, CE treatment
stabilized HRD1 protein expression (Figure 4H), and this was un-
altered by proteasome inhibition (Figure 4I), demonstrating that
CE prevent HRD1 proteasomal degradation. Notably, treatment
with CE, BZA, and the combination CE+BZA also stabilized
HRD1 protein expression in Tg-exposed cultured islets obtained
from human female donors (Figure 4J).
The suppressor/enhancer of Lin-12-like (SEL1L) is a mem-
brane adaptor protein that acts as a scaffold for HRD1 (Figure 4A)
(Iida et al., 2011). Acute conditional SEL1L knockdown in mice
results in a rapid degradation of HRD1 protein in the pancreas,
demonstrating that SEL1L promotes HRD1 protein stability
in vivo. We tested the possibility that activation of ERa stabilizes
HRD1 via increasing SEL1L. In Ins2+/Akita cells exposed to Tg,
treatment with CE and the ERa agonist PPT (but not BZA alone)
increased SEL1L protein compared to vehicle treatment (Figures
5A and 5B). We wondered whether SEL1L is instrumental in the
effect of CE-ERa to protect b cells via stabilization of HRD1
following SEL1L small interfering RNA (siRNA) knockdown in
Ins2+/Akita cells. Following a 50% knockdown of SEL1L protein,
the ability of CE to stabilize HRD1 protein expression was abol-
ished (Figure 5C), and, as a result, the ability of CE to suppress
CHOP protein expression was blocked (Figure 5D), together
demonstrating that SEL1L is instrumental in the ability of CE to
stabilize HRD1 protein and mitigate ER stress. Like in the case
of HRD1, CE increased SEL1L protein in Ins2+/Akita cells exposed
to Tg without increasing SEL1L mRNA levels (Figure 5E), sug-
gesting that CE also promote the stabilization of SEL1L protein.
We assessed SEL1L protein turnover like in the case of HRD1. In
the absence of CE, SEL1L was progressively degraded (Fig-
ure 5F) by proteasomal degradation (Figure 5G). However, CE
prevented SEL1L proteasomal degradation (Figures 5H and 5I).
Importantly, treatment with CE, BZA, and the combination
CE+BZA also stabilized SEL1L protein in Tg-exposed cultured
islets obtained from human female donors (Figure 5J). Of note,
Tg decreases SEL1L mRNA and protein, suggesting that ER
stress itself alters SEL1L expression (Figures 5A and 5E).
Membrane and Nuclear ERa Stabilize the ERAD by
Inhibiting the Ubiquitin-Conjugating Enzyme UBC6e
The E2 ubiquitin-conjugating enzyme UBC6e (Ube2j1 gene) is
the only UBC to localize to the ER and to physically interact via
its transmembrane domain with SEL1L (Burr et al., 2011; Hagi-
wara et al., 2016). In fact, UBC6e is considered an ERAD
degrader, and UBC6e KO mouse embryo fibroblasts exhibit
increased expression of SEL1L (Hagiwara et al., 2016) (like
CE-treated cells). Therefore, we investigated the possibility
that UBC6e is ERa’s primary target in the stabilization of the
SEL1L-HRD1 ERAD complex. In Ins2+/Akita cells exposed to Tg,
treatment with CE and the ERa agonist PPT suppressed
UBC6e mRNA suggesting that CE activation of ERa suppresses
UBC6e gene transcription (Figure 6A). Further, consistent with
previous data described above, BZA suppressed UBC6e
mRNA in female WT mouse islets, but had no effect in age-
matched male islets (Figure 6B). Note that Tg increased
UBC6e mRNA, suggesting that ER stress itself increases
UBC6e gene expression (Figure 6B). Importantly, the ability of
CE, BZA, and the combination CE+BZA to decrease UBC6e pro-
tein expression was translated to Tg-exposed cultured islets ob-
tained from adult human female donors (Figure 6C). To confirm
that downregulation of UBC6e was instrumental in the ability of
CE-ERa to stabilize ERAD proteins and protect b cells from
chronic ER stress, we overexpressed UBC6e in Ins2+/Akita cells.
Following a 2-fold increase in UBC6e protein expression (which
was unresponsive to suppression by CE), the basal expression
of HRD1 and SEL1L proteins was decreased and the ability of
Figure 5. CE-ERa Prevents HRD1 Degradation and ER Stress via SEL1L Stabilization
(A and B) Male Ins2+/Akita cells were treated with CE and BZA (A) or PPT (B) for 24 hr, followed by exposure to Tg for 4 hr. Representative image of western blot for
SEL1L expression and bar graph of quantification (n = 4–8 distinct experiments/condition).
(C and D) Male Ins2+/Akita cells were transfected with mouse SEL1L-specific siRNA or with a control siRNA and were treated like in (A). Protein expression for
SEL1L, HRD1 (C), and CHOP (D) were analyzed by western blotting and quantification (n = 4–6 experiments).
(E) Male Ins2+/Akita cells were treated like in (A) and qRT-PCR quantification of relative SEL1L mRNA was performed and represented as expression relative to
vehicle+Tg. n = 8–9 distinct experiments/condition.
(F–I) Male Ins2+/Akita cells were treated with cycloheximide (CHX) plus Tg and vehicle (F and G) or CE (H and I) in the presence (G and I) or absence (F and H) of
MG132 for the indicated time course. SEL1L protein was quantified by western blot and relative SEL1L protein levels were determined by densitometry and
normalized to that obtained at time 0 (n = 4–6 distinct experiments/condition).
(J) Islets from female human donors were treated like in (A). Representative image of western blot for SEL1L protein expression and bar graph of quantification
(n = 3 experiments).
Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 6. CE-ERa Stabilizes ERAD in b Cells by Inhibiting UBC6e
(A)Male Ins2+/Akita cells were treatedwith the indicated compounds for 24 hr followed by exposure to Tg for 4 hr. qRT-PCR quantification of relative UBC6emRNA
levels is shown (n = 8 experiments/condition).
(B) Female and male WT mouse islets were treated with BZA for 24 hr followed by exposure to Tg for 4 hr, and UBC6e mRNA level were quantified by qRT-PCR
(n = 9–15 distinct experiments/condition).
(C) Islets from female human donors were treated like in (A). Western blot for UBC6e protein expression and bar graph of quantification (n = 3 experiments).
(legend continued on next page)
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CE to stabilize HRD1 and SEL1L was abolished (Figure 6D),
demonstrating that UBC6e is a critical target of ERa to stabilize
the ERAD complex. Further, following UBC6e overexpression,
the basal expression of UPR sensors was increased, and
the ability of CE to suppress the expression of BiP protein,
s-XBP-1 and ATF4 mRNAs was abolished (Figure 6E), confirm-
ing that UBC6e is instrumental in the ability of CE to resolve
the activation of the three arms of the UPR. We next investigated
the mechanism by which CE-ERa suppresses UBC6e. Pools of
nuclear or membrane ERa can mediate estrogens’ actions in
b cells (Tiano andMauvais-Jarvis, 2012). To assess the contribu-
tion of nuclear ERa, we used a knockin mouse with mutant ERa
that precludes ERa palmitoylation andmembrane localization. In
this ‘‘nuclear only ERa’’ (NOER) mouse, ERa is exclusively nu-
clear, and membrane/extranuclear actions of ERa are abolished
(Pedram et al., 2014, 2015). In contrast, we also used an ERa-d-
eficient mouse re-expressing ERa selectively at the plasma
membrane, the membrane-only estrogen receptor-a (MOER)
mouse (Pedram et al., 2009). In islet cells from female WT and
NOERmice exposed to Tg, treatment with CE or BZA decreased
UBC6e mRNA (Figure 6F) and accordingly CE and BZA
completely suppressed CHOP nuclear expression (Figure 6G).
However, the effect of CE or BZA to suppress UBC6e mRNA
expression and CHOP nuclear expression was, respectively,
abolished and reduced in MOER cells (Figures 6F and 6G).
Thus, CE and BZA suppress UBC6e gene expression in b cells
and protect against ER stress mainly through nuclear ERa
signaling (and partially via membrane ERa signaling). Next, we
sought to determine to what extent nuclear ERa requires ERa
binding an estrogen-response element (ERE) on the promoter
of the UBC6e gene (Ube2j1). We used the ERa DNA-binding
domain mutant mouse (ERa-EAAE), which does not support
E2-mediated transcription and lacks the ability to bind perfect
consensus EREs, 1-nt variant EREs, and a small subset of 2-nt
variant EREs (Hewitt et al., 2014). In islet cells from female
EAAE mice exposed to Tg, treatment with CE or BZA failed to
suppress UBC6e mRNA expression compared to WT islets,
demonstrating that ERa suppresses Ube2j1 via a nuclear recep-
tor functional enhancer (NRFE) ERE (Figure 6F) (Coons et al.,
2017). Next, we looked at locations of EREs on the chromosome
that contains theUbe2j1 gene in the mouse and human genome.
No NRFE ERE is present in the promoter of Ube2j1 in either the
mouse or human genome (Figure S5). The closest perfect ERE is
located 400 kb upstream to the transcription start site (TSS)
of Ube2j1 in the mouse genome and 500 kb in the human
genome. The closest 1-nt variant EREs are located 12 and
88 kb upstream of the TSS of Ube2j1 (Figure S5), respectively.
Thus, CE suppress UBC6e via ERa acting on a NRFE ERE, likely
in a distant enhancer, but not on the Ube2j1 promoter.
That CE and BZA each failed to suppress UBC6e mRNA but
partially suppressed CHOP activation in female MOER b cells
(cf. Figures 6F and 6G) suggested that membrane ERa may
also help resolve ER stress independently from suppressing
Ube2j1 transcription. To address this issue, we used an estrogen
dendrimer conjugate (EDC) that remains outside the nucleus and
is the gold standard for studying extra-nuclear ERa actions
(Chambliss et al., 2010; Harrington et al., 2006). In Ins2+/Akita
cells, EDC, like CE, suppressed UBC6e protein expression (Fig-
ure 6H). However, unlike CE, EDC failed to suppress UBC6e
mRNA (Figure 6H), suggesting that ERa extranuclear actions
promote UBC6e protein degradation. To address this issue,
we studied UBC6e protein turnover. Compared to vehicle,
EDC treatment destabilized UBC6e protein (Figure 6I), and this
was abolished by proteasome inhibition (Figure 6I). Together,
this demonstrates that EDC activation of extranuclear ERa pro-
motes UBC6e proteasomal degradation.
BZA Antagonizes ERa Action on EREs in Male b Cells
BZA suppresses b cell apoptosis and protects functional b cell
mass, thus preventing the onset of diabetes in OVX female Akita
mice (Figures 1 and 2). However, BZA does not provide b cell
protection in adult male Akita mice and even reverses the effect
of CE (Figures 1 and 2). Further, BZA suppresses ER stress via
ERa in cultured female Akita b cells, but not in male Akita b cells
(Figure 3). Therefore, unlike CE and E2, which are pure ERa
agonists in b cells from both sexes, BZA is an ERa agonist selec-
tively in female b cells. In male Ins2+/Akita cells, CE’s agonist
action on ERa decreases the activation of the UPR markers
BiP, ATF4, and sXBP-1 and as a result suppresses CHOP
expression (Figure 3). In addition, CE suppress UBC6e mRNA
and protein expression and therefore stabilizes HRD1 and
SEL1L from proteasomal degradation (Figures 4, 5, and 6). In
contrast, in male Ins2+/Akita cells, BZA does not suppress UPR
pathways (Figure 3), does not decrease UBC6e expression (Fig-
ure 6B) and does not stabilize SEL1L-HRD1 ERAD proteins (Fig-
ures 4, 5, and 6), suggesting that BZA is an ERa antagonist in
male b cells.
We first explored the possibility that BZA could be a selective
estrogen receptor degrader (SERD) in male b cells. The ERa is a
short lived protein whose stability is influenced by the nature of
(D) Male Ins2+/Akita cells were transfected with mouse UBC6e or control expression plasmids and treated like in (A). Western blot for UBC6e, SEL1L, and HRD1
protein expression (upper panel) and bar graph of quantification (lower panel) are shown (n = 4–10 distinct experiments/condition).
(E) Male Ins2+/Akita cells were transfected with mouse UBC6e or control plasmids and treated like in (A). Western blot for BiP protein (upper panel) and bar graph of
qRT-PCR quantification of spliced-XBP1 and ATF4 mRNAs (lower panel) (n = 6 distinct experiments/condition).
(F) Cultured islets from female WT, NOER, MOER, and EAAE mice were treated like in (A), followed by qRT-PCR quantification of relative UBC6e mRNA levels
(n = 6 distinct experiments/condition).
(G) Dispersed islets from female WT, MOER, and NOER mice were treated like in (A). Images of IF staining for CHOP, insulin, and nuclei and quantification of
b cells with CHOP+ nuclei relative to vehicle (n = 4–6 experiments).
(H) Male Ins2+/Akita cells were treated with the indicated compounds for 24 hr, followed by exposure to Tg for 4 hr. Protein expression (upper panel) and mRNA
level (lower panel) of UBC6e (n = 6–10 distinct experiments/condition).
(I) Male Ins2+/Akita cells were treated with CHX plus Tg and either vehicle or EDC in the presence or in the absence of MG132 for the indicated time course. UBC6e
protein wasmeasured bywestern blot and relative UBC6e protein levels were determined by densitometry andwere normalized to that obtained at time 0 (n = 3–6
experiments).
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the bound ligand (Wijayaratne and McDonnell, 2001). The half-
life of ERa in both breast and uterine tissues in the absence of
ligand is 5 hr. However, upon binding E2 or the pure ER antago-
nist fulvestrant, the half-life of mouse ERa decreases to 2 and
0.5 hr, respectively (Dauvois et al., 1992). SERDs are drugs
that bind to and induce a conformational change in ERa that tar-
gets it for proteasomal degradation in breast tissue. BZA is a
pure ERa antagonist in breast but is also a SERD, because
BZA degrades ERa in breast cells, thus eliminating its target
(Wardell et al., 2013). To determine whether BZA is a SERD in
male b cells, we studied ERa protein turnover in male Ins2+/Akita
cells (Wijayaratne and McDonnell, 2001). As previously
described, BZA promoted ERa protein degradation in MCF-7
cells producing less than 50% protein expression within 24 hr
(Figure 7A) (Wardell et al., 2013; Wijayaratne and McDonnell,
2001). In contrast, after 24-hr exposure, BZA did not alter ERa
turnover and did not change ERa protein expression in Ins2
+/Akita
and MIN6 cells (Figure 7B).
Having established that BZA is not a SERD in male b cells, we
sought to determine to what extent it is an ERa antagonist.
Agonist-activated ERa downregulates the expression of its
own gene (Esr1), via an ERE on the Esr1 promoter (Tiano et al.,
2015). Accordingly, BZA suppressed ERa mRNA in female WT
mouse islets (Figure 7C). In contrast, BZA showed no effect on
ERa mRNA in age-matched male islets (Figure 7C). Consistent
with these results, in male Ins2+/Akita cells transfected with an
ERE reporter construct, E2 and CE activated ERE signaling (Fig-
ure 7D), but BZA had no effect on ERE activation. Further, and
Figure 7. BZA Antagonizes ERa Actions in Male b Cells
(A) MCF-7 cells were treated with vehicle, CE (107 M), BZA (106 M), or CE+BZA for 24 hr (upper panel). MCF-7 cells were treated with BZA (106 M) for the
indicated time points during 24 hr (lower panel). Cell lysates were subjected to western blot using anti-mouse ERa antibody. Quantification by densitometry is
shown in adjacent bar graph (n = 4).
(B) Ins2+/Akita cells (upper panel) were treated with vehicle, CE (107 M), BZA (106 M), or CE+BZA for 24 hr (upper panel). MIN6 cells (lower panel) were treated
with BZA (106 M) for the indicated time points during 24 hr (n = 4). Cell lysates were treated like in (A).
(C) Female and male WT mouse cultured islets were treated with BZA for 24 hr like in (A), and the ERamRNA levels were quantified by qRT-PCR in the indicated
groups (n = 9–12 distinct experiments/condition).
(D) MIN6 cells were transfected with ERE-Luc plasmid, followed by treatment with the indicated compounds and quantification of luciferase activity (n = 4–10
experiments distinct experiments/condition). Data are shown as mean ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001.
(E) Proposed mechanism for ERa activation of ERAD in b cells. Estrogens activation of nuclear ERa promote transcriptional repression of the UBC6e gene via an
ERE, whereas estrogens activation of membrane ERa promote the proteasomal degradation of UBC6e protein. The resultant decrease in UBC6e protein
expression and activity stabilizes SEL1L, which, in turn, stabilizes HRD1 and promotes the proteasomal degradation of misfolded insulin. This results in increased
HRD1-mediated ubiquitination and proteasomal degradation of misfolded proinsulin.
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consistent with BZA antagonizing ERa actions on EREs, BZA
reversed CE and E2 activation of the ERE (Figure 7D).
DISCUSSION
CE treatment mitigates ER stress in cultured Akita b cells and in
male and female islets from Akita mice, thereby preventing b
cell apoptosis, maintaining insulin secretion and delaying dia-
betes onset. CE prevention of b cell failure in Akita mice could
be partially mediated via non-islet cells effects easing the meta-
bolic stress on b cells. However, extensive evidence demon-
strates that estrogens protect b cell survival and function in vivo
in rodents and cultured human islets via direct effect on ERa in
b cells (Kilic et al., 2014; Le May et al., 2006; Liu et al., 2009,
2013; Tiano et al., 2011; Tiano and Mauvais-Jarvis, 2012;
Wong et al., 2010). Therefore, it is likely that in the Akita model
of pure insulin deficiency, CE prevent diabetes via a direct
b cell effect preventing ER stress. In fact, in Akita cells CE
decrease nuclear expression of CHOP and suppresses the
activation of UPR sensors ATF6, IRE1a, and PERK (assessed
by their proximal markers BiP, sXBP-1, and ATF4, respectively),
demonstrating that CE relieve the ER from the chronic stress of
protein misfolding. Two mechanisms can minimize ER stress: a
pre-emptive upregulation of the UPR to restore proteostasis or
the suppression of the stress itself via either activation of chap-
erones or enhancement of the ERAD, decreasing misfolded
protein accumulation. We find that CE stabilize the ERAD that
promotes the proteasomal degradation of misfolded proteins.
The importance of the ERAD in cellular health cannot be under-
stated, since multiple human diseases are linked to ERAD fail-
ure (Qi et al., 2017). In Akita cells, the ERAD participates in the
turnover of mutant C96Y proinsulin in the ER, but is not suffi-
ciently activated to prevent apoptosis (He et al., 2015). We
show that CE promote ERAD activation by stabilizing its main
effector, the E3 ubiquitin ligase HRD1, which accelerates the
ubiquitination and proteasomal degradation of misfolded C96Y
proinsulin. Using a cellular system validated to compare mutant
and WT proinsulin ubiquitination and degradation in the pres-
ence of HRD1 (Allen et al., 2004), we confirm that CE increase
HRD1-mediated ubiquitination of C96Y proinsulin, which is
associated with a selective C96Y proinsulin destabilization.
Thus, in the presence of HRD1, CE promote the preferential
degradation of misfolded C96Y over WT proinsulin, potentially
decreasing the dominant-negative effect of C96Y proinsulin
that prevents WT proinsulin from exiting the ER, and being
secreted as insulin (Haataja et al., 2016). We show that CE
treatment prevents SEL1L protein degradation, and this is crit-
ical to stabilize HRD1 protein. Indeed, when SEL1L protein
expression is knocked down by 50% in Akita cells, CE fail to
stabilize HRD1 protein and fails to prevent ER stress.
CE stabilizes the ERAD andmitigates ER stress in b cells via its
main receptor ERa. In the absence of ERa, CE fail to suppress
pharmacologically induced ER stress in cultured female islets.
ERAD degraders prevent ERAD-mediated premature degrada-
tion of functional proteins that have not yet attained their folded
conformation, and therefore HRD1 and SEL1L are short-lived
proteins (Noack et al., 2014). CE activation of ERa stabilizes
SEL1L and HRD1 proteins in Akita cells by preventing their pro-
teasomal degradation by the ERAD degrader and ubiquitin-
conjugating enzyme UBC6e. UBC6e is the only UBC to localize
to the ER, and one of its main targets is SEL1L (Hagiwara
et al., 2016). We show that CE activation of ERa in the nucleus
of b cells promotes the transcriptional repression of the UBC6e
gene via an ERE, and this is associated with decreased CHOP
nuclear expression. However, CE acting on membrane pools
of ERa also accelerates the proteasomal degradation of
UBC6e protein. Therefore, in the absence of ERa activation
(OVX Akita females), UBC6e protein expression is increased
and stabilized in Akita b cells, which promotes SEL1L-HRD1 pro-
teasomal degradation, allowing misfolded proinsulin accumula-
tion. In the presence of estrogens, the activation of nuclear
ERa suppresses the production of new UBC6e mRNA and pro-
tein, while the activation of membrane ERa promotes the degra-
dation of existing UBC6e protein. Together these effects
decrease UBC6e protein expression and activity, stabilizing
the ERAD and restoring b cell proteostasis.
UBC6e inhibition is central to the effects of CE, as overexpres-
sion of UBC6e in Akita cells by only 2-fold (which prevents CE
suppression of UBC6e) blocks the ability of CE to stabilize
HRD1 and SEL1L, and to suppress the activation of the
UPR. Importantly, in cultured islets from human female donors
exposed to pharmacologically induced protein misfolding,
treatment with CE, BZA, and the combination CE+BZA also
suppresses UBC6e protein expression, stabilizes SEL1L-HRD1
proteins, and reduces CHOP protein, demonstrating the transla-
tional potential of this finding to protect b cells in women. We
propose that the mechanism of estrogens’ protection of b cell
survival against gluco-lipotoxicity, proinflammatory cytokines,
and oxidative stress (all conditions promoting ER stress) is a pro-
motion of ERAD-mediated misfolded proinsulin degradation
and promotion of b cell proteostasis via suppression of UBC6e
(Figure 7E).
Another important finding is that bazedoxifene, a SERM that
exhibits ERa antagonist activity in breast and uterus and is
used in combination with CE during menopausal therapy, is an
ERa agonist in female b cells. In contrast, bazedoxifene is an
ERa antagonist on EREs in male b cells. In OVX female Akita
mice, bazedoxifene decreases b cell apoptosis thus preventing
the onset of diabetes. Further, bazedoxifene suppresses ER
stress in cultured female Akita b cells. The combination of CE
with bazedoxifene has similar protective activity in female
cultured b cells and in vivo. Finally, bazedoxifene suppresses
UBC6e in female islets via ERa action on a functional ERE. In
contrast, bazedoxifene does not provide b cell protection in adult
male Akita mice and cells. Further, unlike CE, bazedoxifene does
not stabilize HRD1 and SEL1L proteins and does not mitigate ER
stress in male Akita b cells. Unlike in female islets, bazedoxifene
has no effect on UBC6e mRNA expression and cannot suppress
the ERE-regulated Esr1 gene in male islets. Finally, in male Akita
b cells transfected with an ERE reporter construct, we confirm
that bazedoxifene reverses the agonistic effect of CE and E2
on ERE signaling, demonstrating that bazedoxifene is an ERa
antagonist regarding ERE-mediated transcription in these cells.
This is a unique example of a ligand that acts as an agonist of
a nuclear receptor in females but an antagonist of the same re-
ceptor in males.
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What is the mechanism of bazedoxifene sexually dimorphic
activation of ERa in b cells? The ERa agonistic/antagonistic pro-
file of a ligand in female cells depends on cell-specific features of
the cellular environment (Mauvais-Jarvis et al., 2013; Nilsson
et al., 2001). The activity of ERa is controlled by the binding of es-
trogens or SERMs to the ligand-binding domain which triggers
conformational changes of ERa, receptor dimerization and bind-
ing to EREs on DNA, as well as interaction with coregulators
(chromatin remodelers, coactivators, and corepressors). Each
SERM induces a unique ERa conformation (Lonard and
O’Malley, 2006). Therefore, the sex-dimorphic response of ERa
to BZA in b cells could be driven by sex-specific cellular environ-
ments promoting recruitment of sex-specific coregulator com-
plexes to ERa and leading to different responses in male and
females (McDonnell and Wardell, 2010). Unfortunately, this
cellular environment cannot be reliably studied in culture. Sex
differences are dynamic and changeable properties of the
body influenced by sex chromosomes and sex hormones (Mau-
vais-Jarvis et al., 2017a). The resultant in vivo male and female
environments differ in multiple factors that produce different bio-
logical systems for male and female cells in vivo that cannot be
replicated in cell culture (Mauvais-Jarvis et al., 2017a).
There are clinical ramifications to this study. First, the effect of
CE to delay T2D onset in postmenopausal women could be due,
at least partially, to prevention of misfolded proinsulin accumula-
tion. The new combination of CE with bazedoxifene is an ERAD
activator that opens translational potential to protect b cells in
postmenopausal women. Second, several insulin gene muta-
tions producemisfolded proinsulin and neonatal insulin-deficient
diabetes in humans, including the C96Y Akita (Liu et al., 2010).
Further studies are warranted to determine if selective estrogen
ligands can promote C96Y proinsulin insulin degradation and
prevent diabetes in humans. Third and finally, this study has
far-reaching clinical implications for other conditions associated
with protein misfolding (i.e., Alzheimer’s disease and Parkinson
disease).
EXPERIMENTAL PROCEDURES
Experimental Animals and Treatments
Male and female heterozygous Akita (C57BL/6-Ins2Akita/J, Jackson Labora-
tory) mice were treated daily with oral gavage of vehicle or active compounds
at the following dosage: CE (2.5 mg/kg/day) and BZA (3 mg/kg/day). Female
Akita mice were subjected to ovariectomy or sham operation prior to oral treat-
ments. Following completion of treatments, mice were euthanized, and the
pancreata were immediately removed and weighed. Experiments were per-
formed in compliance with Tulane University Institutional Animal Care and
Use Committee (IACUC) and in accordance with NIH guidelines.
Metabolic Studies
Random-fed blood glucose was measured by tail bleeding. For the GTT, mice
were fasted overnight for 15 hr prior to intraperitoneal (i.p.) injection of glucose
(2 g/kg). Blood glucose concentrations were measured using a TRUEresult
GlucoseMeter (Nipro Diagnostics). Plasma insulin levels were quantified using
the Rat/Mouse Insulin ELISA Kit (Millipore).
Quantification of b Cell Mass
This was performed by morphometric analysis (Tiano et al., 2011). Paraffin-
embedded 5-mm-thick sections were incubated with polyclonal guinea pig
anti-insulin primary antibody (1:1,000 dilution, Linco). Insulin-stained sections
were visualized using Cy-3 conjugated donkey anti-guinea pig secondary anti-
body (Jackson Immunoresearch). Insulin-positive cells were imaged with Ni-
kon Eclipse Ti-S epifluorescent microscope at 203 magnification. Pictures
of entire pancreas sections were obtained with Aperio ScanScope slide scan-
ner. Insulin-positive cell areas were quantified with ImageJ software. The b cell
mass was calculated as pancreas weight (mg) multiplied by the percentage of
insulin-positive islet area.
Quantification of b Cell Apoptosis
This was performed using TUNEL (In Situ Cell Death Detection Kit, TMR red,
Roche Diagnosis), insulin antibody, and nuclear DAPI. The percentage of
apoptotic cells was determined by dividing the number of TUNEL/insulin/
DAPI-positive cells by the number of insulin-positive cells in each islet.
Transmission Electron Microscopy
Islets were fixedwith 2%paraformaldehyde/2.5%glutaraldehyde/100mMso-
dium cacodylate buffer at the Molecular Microbiology Imaging Facility of
Washington University School of Medicine in St. Louis. b cells were imaged
with transmission electron microscopy (TEM) at 10,0003 magnification. We
quantified mitochondrial area and ER dilation in b cells of at least 7 TEM fields
using ImageJ. The ER lumen was measured at three different positions, and
the mean value was calculated.
Cell Culture and Treatments
Ins2+/Akita cells were obtained from Dr. Koizumi Laboratory at Kyoto University
and cultured in phenol red-free DMEM medium (D5921, Sigma-Aldrich), sup-
plemented with 15% charcoal stripped-fetal bovine serum (CS-FBS)-contain-
ing vehicle (ethanol), BZA (107 M), CE (108 M), or the combination of BZA
and CE. CE were prepared with the 10 components of Premarin (Pfizer) (Ber-
rodin et al., 2009) (Table S2). After incubation with compounds for 24 hr, cells
underwent ER stress induction via Tg (200 nM) for 4 hr.
Mouse Islet Isolation and Dispersion
Mouse islet isolation was performed as previously described (Tiano et al.,
2011). Briefly, the common bile duct was cannulated, and the pancreas was
perfused with solution of Hank’s balanced salt solution (HBSS) containing
collagenase (1.5 mg/mL, Sigma-Aldrich). Pancreas was excised, digested
for 10 min, and rinsed with ice-cold HBSS. Islets were hand-picked under a
dissection microscope and transferred into a dish filled with RPMI-1640 me-
dium (GIBCO), supplemented with 10% CS-FBS containing compounds.
The following day, islets were dispersed in individual cells using Trypsin
(0.05%) and transferred into chamber slides (#154534, Thermo Scientific)
with the same treatment. After 24 hr, dispersed islet cells were treated with
Tg and compounds for 4 hr. Cells were fixed with 10% formalin and processed
for immunostaining.
Human Islet Culture
Human islets from non-diabetic female donors were provided by the Inte-
grated Islet Distribution Program and cultured in phenol-red-free CMRL
1066 medium (15-110-CV, Corning) supplemented with 10% CS-FBS and
L-glutamine (2 mM). The next day, islets were replenished with fresh medium
and treated as mouse islets.
Plasmid DNA and siRNA Transfection
Mouse Hrd1 gene open reading frame (ORF) cDNA expression plasmid and
mouse Ubc6e gene ORF cDNA expression plasmid was purchased from Ori-
gene (pCMV6-Hrd1 and pCMV6-Ubc6e). Insulin-2-HA-pcDNA3, insulin-2
C96Y-HA-pcDNA3, and Flag Ub WT plasmid were obtained as described (Al-
len et al., 2004). hERa/pcDNA3.1 plasmid was provided by Brian Rowan from
Tulane University. Plasmids were purified with QIAGEN Plasmid Maxi Kit
(QIAGEN). For SEL1L knockdown experiments, small interfering RNAs
(siRNAs) specific for mouse SEL1L (Silencer Select Pre-Designed siRNA)
and a non-targeting negative control siRNA (Silencer Select Negative Control)
were purchased from Thermo Fisher Scientific. Transient transfections of
plasmid DNA were performed using Lipofectamine 2000 reagent (Thermo
Fisher Scientific). Transfections of siRNAs were performed with Lipofectamine
RNAiMAX Transfection Reagent (Thermo Fisher Scientific).
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Protein Stability Assay
Ins2+/Akita cells cultured in phenol red-free DMEMmedium supplemented with
15% charcoal-stripped fetal bovine serum (CS-FBS) containing compounds
for 24 hr. Cells were treated with Tg and compounds for 1 hr, followed by treat-
ment with cycloheximide (CHX, 100 mg/mL, Sigma-Aldrich), and harvested at
the indicated time points. The proteasome inhibitor MG132 (10 mM, Sigma-Al-
drich) was added alongwith CHXwhen necessary. Cell lysates were subjected
to western blotting.
Western Blot
Protein extracts from cells or islets were obtained using M-PER Mammalian
Protein Extraction Reagent (Thermo Fisher Scientific) supplemented with pro-
tease inhibitor (Roche Applied Science). Protein lysates were resolved by
SDS-PAGE. The following primary antibodies were used for immunoblotting:
CHOP (2895, Cell Signaling), HRD1 (sc-130889, Santa Cruz), SEL1L
(ab78298, Abcam), UBC6e (sc-292491, Santa Cruz), Actin (sc-1616, Santa
Cruz) and a-Tubulin (MS-581-P0, Neomarkers).Western blots were developed
with enhanced chemiluminescence (Supersignal West Pico Chemilumines-
cent Substrate, Thermo Fisher Scientific). The band intensities were quantified
using ImageJ.
qRT-PCR
Total RNA from was extracted using the RNeasy Plus Mini Kit (QIAGEN) and
reverse transcribed into cDNA using an iScript cDNA Synthesis kit (Bio-
Rad). qPCR was performed using iTaq Universal SYBR Green Supermix
(Bio-Rad) and the iCycler iQ Real-Time PCR Detection System (Bio-Rad).
b-actin was used as the housekeeping gene.
Transient Transfection of COS-7 Cells and Analysis of Proinsulin
Ubiquitination and Stability
COS-7 cells were placed in CS-DMEM and high-glucose medium with 10%
CS-FBS. Transient transfections were carried out using 1.5 mg cDNA/well
and Polyfect (QIAGEN). The cells were transfected with hemagglutinin A
(HA)-WT proinsulin or HA-C96Y proinsulin along with ERa and FLAG-ubiquitin
in the absence or in the presence of HRD-1 (0.375 mg/plasmid). Cells were
treated with compounds starting 24 hr after transfection, and, at 48 hr, Tg
(20 nM) was added for 4 hr. Whole-cell protein lysates were resolved by
SDS-PAGE, and western blotting was performed using antibodies against a
HA epitope tag (BioLegend #901513 at 1:2,000) or a Flag epitope tag (Sigma,
#F1804, 1:500). The results were visualized with horseradish peroxidase
(HRP)-conjugated secondary antibodies (Jackson ImmunoResearch) and
enhanced chemiluminescence (Thermo Fisher-Pierce). Immunoprecipitation
of cell extracts was carried out with 300 mg total protein using protein A/B
plus agarose (Pierce, Thermo Scientific) and mouse-anti-HA epitope antibody
(1:100 dilution). The immunoprecipitates were subjected to gel electrophoresis
and immunoblotting with anti-FLAG antibody.
ERE-Luc Transfection and Luciferase Assay
ERE-Luc transfection and a luciferase assay were performed following Wong
et al. (2010). MIN6 cells were cultured in phenol-red-free DMEM and trans-
fected with 0.8 mg of ERE-Luc using 2 mL of Lipofectamine 2000. After 6-hr
incubation, cells were then treated with compounds (E2: 10
8 M) for 24 hr.
Measurement of ERE luciferase activity was performed using a Luciferase
Assay System (Promega). Values are reported as relative luciferase units cor-
rected for protein concentration.
Statistics
Results were presented as means ± SEM and analyzed by Student’s t test or
one-way ANOVA, followed by the Bonferroni test when appropriate using the
Graphpad Prism (v.5) software. p < 0.05 is considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at
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Figure S1. Related to Figure 1. (a) Overnight fasting blood glucose levels in 8-week-old male Akita mice (from 
Fig.1) treated as indicated. Data are shown as mean ± SEM. **P < 0.01. (b) Random fed blood glucose 
concentrations and corresponding blood glucose AUC in male Akita mice of the indicated age receiving E
2
 
treatment starting at 40 days of age. (c) Plasma insulin/blood glucose ratio and corresponding AUC in the same 
groups of mice as in Figure S1b (n=8). Data are shown as mean ± SEM. ***P < 0.001. 
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Figure S2. Related to Figure 2. (a) Representative images for Caspase-3 staining in pancreatic islets from male 
Akita mice from Figure S1b and quantification of Caspase-3 positive cell in the same groups of islets (n=3 
experiments). (b) Pancreatic insulin content in male Akita mice from Figure S1b (n=5-8). (c) Quantification of 
pancreatic β-cell proliferation in male Akita mice from Fig. 2f was quantified by ki-67 staining (n = 3). Data are 
shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.  
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Figure S3. Related to Figure 3. (a) Male Ins2+/Akita β-cells were treated with the indicated compounds for 24h 
followed by exposure to Tg for 4h. Representative Western blot for elf2α protein phosphorylation and total protein 
(left) and relative elf2α phosphorylation/total protein levels quantified by densitometry (right) are shown (n=4 
experiments). (b) Dispersed islets from female WT, ERβKO and (c) GPERKO mice were treated with the indicated 
compounds for 24h followed by exposure to Tg for 4h. Representative images of immunofluorescent staining for 
CHOP (red), insulin (green) and nuclei (blue) and quantification of β-cells with CHOP+ nuclei relative to vehicle are 
shown (n=3 experiments). Data are shown as mean ± SEM. **P < 0.01, ***P < 0.001. 
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Figure S4. Related to Figure 4. COS-7 cells were transfected with HA-wild-type proinsulin or HA-C96Y 
proinsulin along with ERα and HRD1. 48h after transfection, cells were treated with CE (10 nM) or vehicle (V) 
along with 100 mM cycloheximide (CHX) and cell lysates were harvested each hour for four hours.  A zero time 
point sample was obtained prior to treating the cells with CHX -/+ CE. Western blotting was carried out using anti-
HA antibodies. Quantification by densitometry of decay curves for WT and C96Y proinsulin following V or CE 
treatments are shown. Inserts represent the half-life of proinsulin for each condition (t1/2) (n=3 distinct 
experiments/condition). 
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Figure S5. Related to Figure 6. Position of perfect EREs and 1nt variant EREs in front of Ube2j1 in the mouse (left) 
and human (right) genomes. 
  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES  
Quantification of pancreatic β-cell proliferation. Ki-67 staining and insulin staining were performed in pancreas 
sections to identify β-cell proliferation. The pancreas sections were incubated with monoclonal rabbit anti-Ki-67 
antibody (1:200 dilution, Thermo Scientific) and polyclonal guinea pig anti-insulin primary antibody (1: 1000 
dilution, Linco, St Louis, MO). Ki-67 staining and insulin staining were visualized using Cy-3 conjugated donkey 
anti-rabbit secondary antibody (Jackson Immunoresearch) and FITC conjugated donkey anti-guinea pig secondary 
antibody (Jackson Immunoresearch), respectively. All the islets in one pancreas were imaged with Nikon Eclipse Ti-
S epifluorescent microscope at 20x magnification. Insulin staining positive area in each islet was measured with 
ImageJ software. β-cell proliferation was determined by dividing the number of Ki-67/insulin double-positive cells 
by insulin staining positive area (µm2) in each pancreas section.  
 
Caspase-3 Immunohistochemistry Staining. 3, 3-Diaminobenzidine (DAB) (Vector Laboratories) 
immunohistochemical staining complex technique was performed. Briefly, deparaffinized pancreatic sections of 
5μm thickness were rehydrated in ethanol and induced and antigen retrieval procedure using 0.01M Sodium Citrate 
Buffer (pH 6.0). Peroxidase activity was blocked with a solution of 3% hydrogen peroxide and nonspecific antibody 
reactions were blocked with a solution of 1% BSA, 5% goat serum, 0.02% Triton X-100. Sections were incubated 
overnight at 4°C with primary antibody anti-cleaved caspase 3 (Cell Signaling) and 1 hour at room temperature with 
secondary biotinylated anti-rabbit antibody. Sections were placed in an avidin-biotinhorseradish peroxidase (HRP) 
complex (ABC Elite; Vector Laboratories) for 1 hour. After rinsing sections were stained with DAB until medium-
dark brown color was achieved. Finally a nuclear hematoxylin counterstain and dehydration was performed.  
 
ERα western blot. Protein extracts from Ins2+/Akita cells, MCF-7 cells or Min-6 cells were obtained using M-PER 
Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) supplemented with protease inhibitor (Roche 
Applied Science) following the manufacturer’s protocol. Protein lysates were resolved by SDS-PAGE. The 
following primary antibodies were used for immunoblotting: ERα (sc-542, Santa Cruz), Actin (sc-1616, Santa Cruz). 
Western blots were developed with enhanced chemiluminescence (Supersignal West Pico Chemiluminescent 
Substrate, Thermo Fisher Scientific). The band intensities were quantified using ImageJ software. 
 
Identification of Estrogen Response Element (ERE)s in the mouse and human genomes. The location coordinates 
of the perfect and 1 nt variant EREs were identified in the mouse and human genomes using OligoMatch (UCSC) as 
described in Coons et al. 1 Here, the ERE is the motif 5’-GGTCAnnnTGACC-3’.  
 
SUPPLEMENTAL REFERENCES 
1. Coons, L.A., Hewitt, S.C., Burkholder, A.B., McDonnell, D.P. & Korach, K.S. DNA Sequence Constraints 
Define Functionally Active Steroid Nuclear Receptor Binding Sites in Chromatin. Endocrinology 158, 3212-3234 
(2017). 
 
 
  
Table S1, related to Experimental Procedures: the characteristics of the female islet donors 
  
  Donor #1 Donor #2 Donor #3 
Age  49 Years 27 Years 65 Years 
Gender Female Female Female 
Height 67.00 inches 61.00 inches 69.00 inches 
Weight 161.0 lbs 147.0 lbs 238.0 lbs 
BMI 25.2 27.8 35.1 
Ethnicity/Race Black or African American Hispanic/Latino Black or African American 
ABO blood group O B O 
Cause of death Cerebrovascular/stroke Anoxia Cerebrovascular/stroke 
Medical history Clean Clean HTN >10 yrs compliant, 
HLD >10 yrs 
Table S2, related to Experimental Procedures: Composition of conjugated equine estrogens (CE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
